Biotech Values

[genisi]

Master, don't you have these odds [odds of success in non-carrier near 60% and carrier around 25%] reversed?

I think he meant what he wrote because in phase II, the post-hoc ApoE4 subgroups analysis showed good efficacy only in non-carriers.